The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 1 of the 20 sources its claims cite were checked for support.
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
Open accessAbstract
BACKGROUND: Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin-angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available for patients with type 2, the most common form of diabetes. We assessed the role of the angiotensin-II-receptor antagonist losartan in patients with type 2 diabetes and nephropathy. METHODS: A total of 1513 patients were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once daily) with placebo, both taken in addition to conventional antihypertensive treatment (calcium-channel antagonists, diuretics, alpha-blockers, beta-blockers, and centrally acting agents), for a mean of 3.4 years. The primary outcome was the composite of a doubling of the base-line serum creatinine concentration, end-stage renal disease, or death. Secondary end points included a composite of morbidity and mortality from cardiovascular causes, proteinuria, and the rate of progression of renal disease. RESULTS: A total of 327 patients in the losartan group reached the primary end point, as compared with 359 in the placebo group (risk reduction, 16 percent; P=0.02). Losartan reduced the incidence of a doubling of the serum creatinine concentration (risk reduction, 25 percent; P=0.006) and end-stage renal disease (risk reduction, 28 percent; P=0.002) but had no effect on the rate of death. The benefit exceeded that attributable to changes in blood pressure. The composite of morbidity and mortality from cardiovascular causes was similar in the two groups, although the rate of first hospitalization for heart failure was significantly lower with losartan (risk reduction, 32 percent; P=0.005). The level of proteinuria declined by 35 percent with losartan (P<0.001 for the comparison with placebo). CONCLUSIONS: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
35 Own result · 16 Own method · 13 Own interpretation · 7 No full text of the sources · 2 No basis given · 1 Supported so far · 1 Sources not found · 1 Not checked yet
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes, 1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel-antagonist therapy.”
What the sources say
- Not checked — no full text of the sourcecites [1] source
- Supportedcites [28] source
The Randomization and Treatment Plan states that calcium-channel blockers were discontinued before screening and excluded as additional antihypertensive treatment. Irbesartan and the calcium-channel blocker amlodipine were assigned as separate regimens, so this type 2 diabetes study did not test irbesartan's benefit with concurrent calcium-channel-blocker therapy. The captopril study in type 1 diabetes is covered by the sentence's other citations, not this source. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [29] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The level of proteinuria declined by 35 percent with losartan (P<0.001 for the comparison with placebo).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Losartan also reduced the risk of end-stage renal disease by 28 percent (P=0.002)”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“according to the per-protocol analysis, among the patients who continued to receive their assigned study treatment, losartan conferred a 22 percent reduction in the risk of the primary composite end point (P=0.008).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We did find a significant difference in favor of losartan with regard to the rate of a first hospitalization for heart failure, a component of this secondary composite end point.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The risk of the combined end point of end-stage renal disease or death was 20 percent lower in the losartan group than in the placebo group (P=0.01)”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this population, losartan (plus conventional antihypertensive therapy) demonstrated excellent tolerability, similar to that of placebo (plus conventional antihypertensive therapy), as evidenced by the similar numbers of patients in the two groups in whom the study treatment was discontinued because of adverse events.”
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment with losartan resulted in a 16 percent reduction in the risk of the primary composite end point (P= 0.02)”
plaindirectn = 327 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Similarly, simultaneous therapy with calcium-channel antagonists did not detract from the beneficial effects of losartan, despite the recent controversy regarding the role of calcium-channel antagonists in the protection of the kidneys and the heart. 25-27”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Approximately one third of the patients had a fatal or nonfatal cardiovascular event (247 in the losartan group [32.9 percent] and 268 in the placebo group [35.2 percent]; risk reduction, 10 percent; P=0.26).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 14
- Probably not a substantial claim. 16
- The quote only partly states this claim. 1
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was a difference between the number of myocardial infarctions in the losartan group (50 patients [6.7 percent]) and the number in the placebo group (68 patients [8.9 percent]; risk reduction, 28 percent), but this difference was not statistically significant (P=0.08).”
plainn = 50- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There was a small, time-averaged difference in the trough blood pressure between the losartan group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Approximately 20 percent of the patients died, but there was no significant difference in mortality between the two groups (P=0.88).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Losartan also led to an average reduction in the level of proteinuria (the urinary albumin-to-creatinine ratio) of 35 percent, whereas in the patients in the placebo group, the urinary albumin-to-creatinine ratio tended to increase (P<0.001 for the overall treatment effect) (Fig. 3).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mean arterial pressure, 95.9 mm Hg and 96.8 mm Hg, respectively [P=0.59]; pulse pressure, 66.7 mm Hg and 67 .4 mm Hg, respectively [P= 0.77]”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mean arterial pressure, 99.1 mm Hg and 99.7 mm Hg, respectively [P= 0.38]; pulse pressure, 66.2 mm Hg and 67 .1 mm Hg, respectively [P=0.37]”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mean arterial pressure, 100.9 mm Hg and 103.1 mm Hg, respectively [P<0.001]; pulse pressure, 67 .8 mm Hg and 69.8 mm Hg, respectively [P=0.05]”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant differences in the rates of most of the cardiovascular end points; the exception was the first hospitalization with heart failure (89 patients in the losartan group [11.9 percent], as compared with 127 in the placebo group [16.7 percent]), for which the risk was reduced by 32 percent (P=0.005)”
- Also stated in: § A BSTRACT · p. 1 · plain
“although the rate of first hospitalization for heart failure was significantly lower with losartan (risk reduction, 32 percent; P=0.005)”
plaindirectn = 89 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § A BSTRACT · p. 1 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At base line, 93.5 percent of the patients (92.3 percent in the losartan group and 94.6 percent in the placebo group) were receiving antihypertensive therapy.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The benefits of losartan were observed among our patients, many of whom were already receiving other therapies, such as aspirin, beta-blockers, and lipidlowering agents, as part of sound medical practice.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Increased serum concentrations of creatinine or potassium led to the discontinuation of the study medication in 1.5 percent and 1.1 percent, respectively, of the patients in the losartan group, as compared with 1.2 percent and 0.5 percent of the patients in the placebo group.”
plaindirectn = 1,513- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Analyses of the primary and secondary end points were performed according to the intention-to-treat principle; we included data from all randomized patients (with the exception of three patients who were lost to follow-up), from the time of randomization through the date of study termination.”
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An independent end-points committee whose members were unaware of the patients' treatment assignments reviewed the data to determine which patients had reached the end points.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“More patients discontinued the study treatment in the placebo group (53.5 percent) than in the losartan group (46.5 percent).”
plainn = 1,513- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Study was an investigator-initiated, multinational, double-blind, randomized, placebo-controlled study designed to evaluate the renoprotective effects of losartan in 1513 patients with type 2 diabetes and nephropathy.”
plainn = 1,513- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Because one interim analysis used a stopping boundary that was based on an alpha spending function of the O'Brien-Fleming type, 10 a critical P value of 0.048 was required for the primary hypothesis.”
What the sources say
- Not checked — no full text of the sourcecites [10] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In a second, per-protocol analysis, we excluded patients who violated the criteria for inclusion and exclusion and censored patients' data 14 days after they permanently discontinued the study medication.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol was approved by the institutional review board of each center, and all patients gave written informed consent.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the study was discontinued early (February 10, 2001) by a unanimous vote of the steering committee, whose members were unaware of the treatment assignments.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We cannot exclude the possibility that this small difference had a beneficial effect on the renal outcomes.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The Heart Outcomes Prevention Evaluation (HOPE) Study 32 and its substudy of patients with diabetes, MICRO-HOPE, 20 showed benefits of angiotensin-I-converting enzyme inhibition in terms of the signs and symptoms of heart failure but failed to show significant differences in hospitalizations for heart failure.”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Previous studies involving angiotensin-I-converting enzyme inhibitors have demonstrated beneficial effects on proteinuria but have not demonstrated the superiority of blockade of the renin-angiotensin system in slowing the progression to end-stage renal disease over nonblockade forms of therapy. 14-20”
What the sources say
- Not matchedcites [14] Walker WG, 1992, J Am Soc Nephrol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [15] source
- Not checked — no full text of the sourcecites [16] source
- Not checked — no full text of the sourcecites [17] source
- Not checked — no full text of the sourcecites [18] source
- Not checked — no full text of the sourcecites [19] Estacio RO, 2000, Diabetes Care
- Not checked — no full text of the sourcecites [20] source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, in the absence of a direct comparison between angiotensin-I-converting enzyme inhibitors and angiotensin II antagonists, any extrapolation from the results obtained with different classes of drugs is speculative at best.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We were able to determine the status of all patients (except for three patients in the losartan group who could not be contacted) with respect to dialysis, transplantation, and death.”
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Subsequent hospitalizations for heart failure were not assessed.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, the Cox model accounts for the base-line level of proteinuria (which was a stratification factor) and the geographic region, as prespecified in the data analysis plan.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The difference results in part from the fact that the Cox regression model accounts for the time at risk - i.e., the longer average follow-up in the losartan group than in the placebo group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper relies on this without support.
Diabetic nephropathy is the leading cause of end-stage renal disease.
“Diabetic nephropathy is the leading cause of end-stage renal disease.”
The paper relies on this without support.
Type 2 diabetes is the most common form of diabetes.
“type 2, the most common form of diabetes”
The paper relies on this without support.
Similar data on interruption of the renin-angiotensin system are not available for patients with type 2 diabetes.
“similar data are not available for patients with type 2, the most common form of diabetes”
The paper relies on this without support.
Postponing end-stage renal disease in patients with type 2 diabetes remains an elusive goal.
“postponing end-stage renal disease in patients with type 2 diabetes, the leading cause of chronic renal failure in many countries, remains an elusive goal”
The paper relies on this without support.
Type 2 diabetes is the leading cause of chronic renal failure in many countries.
“type 2 diabetes, the leading cause of chronic renal failure in many countries”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the IDNT trial, treatment with irbesartan compared with placebo resulted in a 33% decrease in the risk of doubling of serum creatinine concentration and was associated with a nonsigni fi cant reduction in the incidence of kidney failure, which was independent of blood pressure.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [13]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) has been shown to prevent major adverse kidney outcomes in people with diabetes, and these drugs are recommended by clinical practice guidelines for the treatment of people with type 2 diabetes who have, or are at high risk of, kidney disease.[4][5][6][7][8]”
From SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (2019) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The only currently approved treatment for renoprotection in patients with type 2 diabetes is reninangiotensin system blockade, which was first shown to be effective 18 years ago.3,4”
From Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, a sustained ≥57% decrease in eGFR (equivalent to doubling of serum creatinine) was selected in FIDELITY because it is a classic outcome in diabetic nephropathy studies2 , 12–14 and is a more robust kidney failure surrogate outcome than a ≥40% decrease in eGFR, particularly when initial changes in eGFR occur.14 , 15”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [13]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (68-71), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR ≥300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to kidney failure (72)(73)(74)(75)(76)(77)(78)(79)(80)(81).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ACE inhibitors or ARBs are the preferred first-line agents for blood pressure treatment among people with diabetes, hypertension, eGFR <60 mL/min/1.73m 2 , and UACR ≥300 mg/g creatinine because of their proven benefits for prevention of CKD progression (72,73,75).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This recommendation is based on RCTs where findings demonstrated decreased risk of CKD progression, for which patients with albuminuria are at elevated risk, with a maximally dosed RAS inhibitor compared with placebo or an active antihypertensive drug comparator (42–44).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In patients with diabetic kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors,3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors,6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone8,9 all reduced the risk of progression to kidney failure.”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB)s improve endothelium-dependent vasodilation and reduce morbidity and mortality in heart failure and nephropathy, including diabetic nephropathy.218-221”
From The Vasculature in Prediabetes (2018) · cites this paper as [219]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the IDNT trial, treatment with irbesartan compared with placebo resulted in a 33% decrease in the risk of doubling of serum creatinine concentration and was associated with a nonsigni fi cant reduction in the incidence of kidney failure, which was independent of blood pressure.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“For many years, the only agents that had demonstrated benefit in slowing kidney disease progression were the renin angiotensin aldosterone system blockers of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) [11], [12], [13].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [11]
In the citing paper
“ARBs (irbesartan/telmisartan) also slowed progression from microalbuminuria (albuminuria stage A2) to overt nephropathy.708,709”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [708]
In the citing paper
“Antagonism of the RAAS with ACE inhibitors or AngII receptor blockers also attenuates, but may not completely halt, the progression of kidney injury in patients with obesity, hypertension and T2DM67,68.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [67]
In the citing paper
“Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB)s improve endothelium-dependent vasodilation and reduce morbidity and mortality in heart failure and nephropathy, including diabetic nephropathy.218-221”
From The Vasculature in Prediabetes (2018) · cites this paper as [219]
In the citing paper
“ARBs have also been shown to reduce the rate of progression from micro- to macroalbuminuria as well as ESRD in patients with type 2 diabetes (234–236).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [235]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The mean follow-up time was 3.4 years (42 months).”
Reported 42 · recomputed 40.8
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients · p. 2
“who had any history of heart failure before enrollment.”
§ DISCUSSION · p. 6
“There were 88 patients (44 in each group) who had preexisting heart failure at the time of randomization.”
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
Research works printed but not linked: 5
- Black HR, 1999, J Hypertens, 17, S3
- Levey AS, 2000, J Am Soc Nephrol, 11, 155A
- Walker WG, 1992, J Am Soc Nephrol, 3, 339
- Estacio RO, 2000, Diabetes Care, 23, B54
- Bauer JH, Reams GP. Antihypertensive drugs. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:2253-97.
Cited by
Sorted by citations
Items 3,401–3,500 of 7,495
Holdiness, A. S., Monahan, K., Minor, D. S., et al. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.07.021 · Cited by 17
Management of arterial hypertension in obese patients
Wenzel, U. O., & Krebs, C. F. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0090-7 · Cited by 17
Kato, J., Yokota, N., Tamaki, N., KARIYA, S., Kita, T., Ayabe, T., Eto, T., & Kitamura, K. (2010) · Hypertension Research · doi:10.1038/hr.2010.233 · Cited by 17
Combination inhibition of the renin–angiotensin system: is more better?
Krause, M. W., Fonseca, V. A., & Shah, S. V. (2011) · Kidney International · doi:10.1038/ki.2011.142 · Cited by 17
Effectiveness of blood pressure lowering: evidence-based comparisons between men and women
Turnbull, F., Woodward, M., & Anna, V. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.155 · Cited by 17
Novel effective drugs for diabetic kidney disease? or not?
Gentile, G., Mastroluca, D., Ruggenenti, P. L., & Remuzzi, G. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.979151 · Cited by 17
Self-citationHypertension and Cardiovascular Disease
Whaley‐Connell, A. T., Sowers, K. M. R., & Sowers, J. R. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-153-6_28 · Cited by 19
Kröpelin, T. F., de Zeeuw, D., Holtkamp, F., Packham, D., & Heerspink, H. (2016) · Nephrology, Dialysis and Transplantation · doi:10.1093/ndt/gfv429 · Cited by 17
Pathophysiology of Obesity—Induced Hypertension and Target Organ Damage
Hall, J. E., da Silva, A. A., Brandon, E. L., Stec, D. E., Ying, Z., & Jones, D. W. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-03961-1.50041-6 · Cited by 18
Endothelin A receptor antagonists in diabetic kidney disease
Georgianos, P. I., & Agarwal, R. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000342 · Cited by 17
Burggraaf, B., & Cabezas, M. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.04.017 · Cited by 17
Low, S. K., Lim, S. C., Wang, J., Yeoh, L. Y., Liu, A. Y. L., Lim, E. K., Shao, Y. L., Chui, W., Fun, S., Chua, C. L., et al. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12626 · Cited by 17
Shunan, F., Jiqing, Y., & Xue, D. (2018) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320318803495 · Cited by 17
Taylor, K., McLellan, J., Verbakel, J. Y. J., Aronson, J. K., Lasserson, D. S., Pidduck, N., Roberts, N. W., Fleming, S., O’Callaghan, C. A., Bankhead, C. R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030596 · Cited by 17
Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
Leehey, D. J. (2020) · Kidney360 · doi:10.34067/kid.0001252019 · Cited by 18
the directors of the JCS, J., Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00471-5 · Cited by 16
SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
Салухов, В. В., Khalimov, Y. S., Борисович, Ш. С., & Popov, S. I. (2021) · Diabetes Mellitus · doi:10.14341/dm12123 · Cited by 19
Which Patients with Obesity Are at Risk for Renal Disease?
Sandino, J., Luzardo, L., Morales, E., & Praga, M. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000513868 · Cited by 20
Fukui, A., Kaneko, H., Okada, A., Yano, Y., Itoh, H., Matsuoka, S., Morita, K., Kiriyama, H., Kamon, T., Fujiu, K., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab248 · Cited by 16
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 18
Yorioka, N., Kiribayashi, K., Naito, T., et al. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.2.213 · Cited by 17
Uehara, K., Yasuda, T., Shibagaki, Y., & Kimura, K. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000438460 · Cited by 17
What can we learn from the recent blood glucose lowering megatrials?
Chan, J. C. N. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00063.x · Cited by 16
Genetic Polymorphisms and the Risk of Accelerated Renal Function Decline in Women
Worobey, C. C., Fisher, N. D. L., Cox, D. G., Forman, J. P., & Curhan, G. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004787 · Cited by 17
Kinouchi, K., Ichihara, A., Sakoda, M., et al. (2009) · Hypertension Research · doi:10.1038/hr.2009.162 · Cited by 17
Abdi, R., & Brenner, B. M. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2003.11.004 · Cited by 16
Self-citationOlmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes
Ikeda, H., Hamamoto, Y., Honjo, S., Nabe, K., Wada, Y., & Koshiyama, H. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.10.013 · Cited by 17
Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease
Mohtat, D., Thomas, R., Du, Z., Boakye, Y., Moulton, T. A., Driscoll, C. E., & Woroniecki, R. P. (2010) · Pediatric Nephrology · doi:10.1007/s00467-010-1677-9 · Cited by 17
Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus
Reboldi, G., Gentile, G., Angeli, F., & Verdecchia, P. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0160-9 · Cited by 17
Ruiz‐Hurtado, G., & Ruilope, L. M. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu023 · Cited by 18
Huang, Y., Zhou, Q., Haaijer‐Ruskamp, F. M., & Postma, M. J. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-15 · Cited by 17
Yang, Y., Thumula, V., Pace, P. F., Banahan, B. F., Wilkin, N. E., & Lobb, W. B. (2010) · Journal of the American Pharmacists Association · doi:10.1331/japha.2010.09071 · Cited by 17
Prevention of chronic kidney disease: The next step forward! (Review Article)
de Jong, P. E., & Gansevoort, R. T. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00575.x · Cited by 17
Hitomi, H., Mehta, P. K., Taniyama, Y., Lassegue, B. P., Seidel-Rogol, B. L., Martín, A. S., & Griendling, K. K. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00017.2011 · Cited by 17
Cardiorenal Consideration as a Risk Factor for Heart Failure
Obialo, C. I. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.12.016 · Cited by 17
Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension
Shantsila, A., Lane, D. A., Beevers, D. G., & Lip, G. Y. H. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283526e47 · Cited by 17
Shima, A., Miyamoto, M., Kubota, Y., Takagi, G., & Shimizu, W. (2015) · Journal of Nippon Medical School · doi:10.1272/jnms.82.84 · Cited by 17
Rubio-Guerra, A. F., Garro-Almendaro, A. K., Elizalde-Barrera, C. I., et al. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716678538 · Cited by 17
Montero, R., Herath, A., Qureshi, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18595-1 · Cited by 17
The care of patients with chronic kidney disease
Kausz, A. T., & Levey, A. S. (2002) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2002.20634.x · Cited by 17
Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings.
Collins, F. M. (2002) · PubMed · Cited by 17
Antiproteinuric effect of RAS blockade: New mechanisms
Lassila, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0058-9 · Cited by 17
Self-citationProgressive renal and cardiovascular disease: Optimal treatment strategies
Weir, M. R. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00591.x · Cited by 17
Okada, T., Nakao, T., Matsumoto, H., & Nagaoka, Y. (2008) · American Journal of Nephrology · doi:10.1159/000146028 · Cited by 17
Therapeutic Interruption of Advanced Glycation in Diabetic Nephropathy
Sourris, K. C., Forbes, J. M., & Cooper, M. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1433.048 · Cited by 17
Self-citationRandhawa, G. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(02)03879-4 · Cited by 17
ACE inhibitors in cardiac surgery: current studies and controversies
Sun, J.-Z., Cao, L.-H., & Liu, H. (2010) · Hypertension Research · doi:10.1038/hr.2010.188 · Cited by 17
A different approach to resistant hypertension.
Hirsch, S. (2007) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.74.6.449 · Cited by 17
Management of hypertension in hemodialysis patients
Ram, C., & Fenves, A. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0049-y · Cited by 33
In hypertension, the kidney breaks your heart
Crowley, S. D., & Coffman, T. M. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0074-5 · Cited by 17
Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering
Miyata, T., & de Strihou, C. V. Y. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl013 · Cited by 17
Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study
Tershakovec, A. M., Keane, W. F., Zhang, Z., et al. (2008) · Diabetes Care · doi:10.2337/dc07-0196 · Cited by 17
Self-citationMiot, A., Ragot, S., Hammi, W., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2468 · Cited by 17
Katayama, S., Yagi, S., Yamamoto, H., et al. (2007) · Hypertension Research · doi:10.1291/hypres.30.529 · Cited by 17
Preston, R. A. (2007) · Climacteric · doi:10.1080/13697130601114909 · Cited by 17
Cardiovascular manifestations in Marfan syndrome.
Figueiredo, S., Martins, E., Lima, M. R., & Álvares, S. (2001) · PubMed · Cited by 17
Evidence‐based treatment of hypertension in patients with diabetes mellitus
Onuigbo, M. A. C., & Weir, M. R. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00222.x · Cited by 16
Hirohiko, A. B. E., Minatoguchi, S., Ohashi, H., et al. (2007) · Hypertension Research · doi:10.1291/hypres.30.929 · Cited by 17
Anis, A. H., Sun, H., Singh, S., Woolcott, J. C., Nosyk, B., & Brisson, M. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624040-00008 · Cited by 17
Angiotensin II receptor blockade in diabetic nephropathy
Ruddy, M. C. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02320-2 · Cited by 17
Ishimitsu, T., Kameda, T., Akashiba, A., et al. (2005) · Hypertension Research · doi:10.1291/hypres.28.865 · Cited by 17
Ruilope, L. M., Coca, A., Volpe, M., & Waeber, B. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02258-6 · Cited by 17
Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure
Howard, P. A., Cheng, J. W. M., Crouch, M. A., Colucci, V. J., Kalus, J. S., Spinler, S. A., & Munger, M. A. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h059 · Cited by 17
Angiotensin-Receptor Blockers, Type 2 Diabetes, and Renoprotection
(2002) · New England Journal of Medicine · doi:10.1056/nejm200202283460912 · Cited by 16
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 20
Improving outcomes in diabetes and chronic kidney disease: The basis for Canadian guidelines
McFarlane, P. A., Tobe, S. W., & Culleton, B. F. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70806-1 · Cited by 16
Nakamura, T., Sato, E., Amaha, M., Kawagoe, Y., Maeda, S., & Yamagishi, S. (2011) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320311422580 · Cited by 16
Li, Y., Ricardo, S. D., & Samuel, C. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116035 · Cited by 18
A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome
Sano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065983 · Cited by 16
Koya, D., Anker, S. D., Ruilope, L. M., et al. (2023) · American Journal of Nephrology · doi:10.1159/000532102 · Cited by 16
Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease
Górriz, J. L., González‐Juanatey, J. R., Fácila, L., Soler, M. J., Valle, A., & Ortíz, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.002 · Cited by 16
Cardiac Involvement Due to COVID-19: Insights from Imaging and Histopathology
Püntmann, V. O., Shchendrygina, A., Bolanos, C. R., Ka, M. M., Valbuena-López, S., Rolf, A., Escher, F., & Nagel, E. C. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.02 · Cited by 16
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 16
Yi, Y., Kwon, E., Yun, G., Park, S., Jeong, J. C., Na, K. Y., Chin, H. J., Yoo, S., Kim, S., Oh, T. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52078-4 · Cited by 17
Bell, D. S. H., & Jerkins, T. W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15559 · Cited by 17
A new perspective on proteinuria and drug therapy for diabetic kidney disease
Zhang, R., Wang, Q., Li, Y., Li, Q., Zhou, X., Chen, X., & Dong, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349022 · Cited by 21
Dasgupta, I., Zac‐Varghese, S., Chaudhry, K., McCafferty, K., Winocour, P. H., Chowdhury, T. A., Bellary, S., Goldet, G., Wahba, M. M., De, P., et al. (2024) · Diabetic Medicine · doi:10.1111/dme.15450 · Cited by 21
Cardiovascular events and mortality in chronic kidney disease (stages I-IV).
Quiroga, B., Verdalles, Ú., Reque, J., et al. (2013) · PubMed · doi:10.3265/nefrologia.pre2013.may.11895 · Cited by 16
Diastolic Pressure in Type 2 Diabetes
Osher, E., & Stern, N. (2008) · Diabetes Care · doi:10.2337/dc08-s262 · Cited by 16
ACEI/ARB Underused in Patients with Type 2 Diabetes in Chinese Population (CCMR-3B Study)
Xie, Q., Hao, C., Ji, L., Hu, D., Zhu, T., Li, X., Qin, D., & Zhang, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116970 · Cited by 16
Vidal-Pardo, J. I., Pérez-Castro, T. R., López-Álvarez, X. L., Santiago-Pérez, M. I., Soidán, F. J. G., & Muñiz, J. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12145 · Cited by 16
Does cardiovascular protection translate into renal protection?
Ruiz‐Hurtado, G., & Ruilope, L. M. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.97 · Cited by 15
Hase, M., Babazono, T., Ujihara, N., & Uchigata, Y. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12029 · Cited by 15
Takagi, H., & Umemoto, T. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.079 · Cited by 16
Update on role of direct renin inhibitor in diabetic kidney disease
Dhakarwal, P., Agrawal, V., Kumar, A., Goli, K. M., & Agrawal, V. (2014) · Renal Failure · doi:10.3109/0886022x.2014.900425 · Cited by 15
Levin, A., Lancashire, W., & Fassett, R. G. (2013) · Kidney International · doi:10.1038/ki.2013.91 · Cited by 16
Treatment of Arterial Hypertension in Obese Patients
Wenzel, U. O., Benndorf, R. A., & Lange, S. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.009 · Cited by 18
Thilly, N., Boini, S., Kessler, M., Briançon, S., & Frimat, L. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn566 · Cited by 16
Diuretics: still essential drugs for the management of hypertension
Fuchs, F. D. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.32 · Cited by 16
Aliskiren and valsartan combination therapy for the management of hypertension
Epstein, B. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8175 · Cited by 16
An evaluation of renal biopsy in type-II diabetic patients.
Arif, M. K., Arif, M. K., & Arif, M. S. (2009) · PubMed · doi:10.2009/jcpsp.627631 · Cited by 16
Granata, S., Gassa, A. D., Bellin, G., Lupo, A., & Zaza, G. (2016) · BioMed Research International · doi:10.1155/2016/9290857 · Cited by 16
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease
Pena-Polanco, J. E., & Fried, L. F. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.05.009 · Cited by 16
Roles of renin-angiotensin system and Wnt pathway in aging-related phenotypes
Kamo, T., Akazawa, H., Suzuki, J., & Komuro, I. (2016) · Inflammation and Regeneration · doi:10.1186/s41232-016-0018-1 · Cited by 16
Packer, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13191 · Cited by 15
Smith, M. C., Herrington, W. G., Weldegiorgis, M., Hobbs, R. F., Bankhead, C. R., & Woodward, M. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.04.004 · Cited by 15
Wang, M., Wang, Z., Zhou, J., Sun, W., Wang, Y., Han, M., Yang, H., Liu, W. J., & Wang, Y. (2018) · Trials · doi:10.1186/s13063-018-2749-6 · Cited by 16
Vitamin D deficiency and kidney hyperfiltration: a mechanism of kidney injury?
Fakhoury, M., Levy, R. V., & Melamed, M. L. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.06.64 · Cited by 16
Coleman, C. I., Weeda, E. R., Kharat, A. A., Bookhart, B., & Baker, W. L. (2019) · Diabetic Medicine · doi:10.1111/dme.14107 · Cited by 16
Lee, J., Choi, E. H., Son, J., Youn, Y. J., Ahn, S. G., Ahn, M., Kim, J., Lee, S., Yoon, J., Ryu, D. R., et al. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa060 · Cited by 16
Metadata
- Authors
- Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Melbourne (AU)
- Hennepin County Medical Center (US)
- Emory University (US)
- Mario Negri Institute for Pharmacological Research (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-20
- Volume
- 345
- Issue
- 12
- Pages
- 861-869
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2056976690
- Semantic Scholar
- 842bf4da2a50ee13464536c9dfa502f4eb80c5f1
- Cited by
- 7,493
- References
- 37
- Citations by year
- 2026: 180 · 2025: 233 · 2024: 211 · 2023: 248 · 2022: 235 · 2021: 240 · 2020: 263 · 2019: 204 · 2018: 212 · 2017: 233 · 2016: 243 · 2015: 249 · 2014: 289 · 2013: 288 · 2012: 341
- FWCI
- 280.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Keywords
- losartan, type 2 diabetes, diabetic nephropathy, angiotensin receptor blockers, renin-angiotensin system blockade, end-stage renal disease, kidney disease progression, proteinuria, cardiovascular morbidity and mortality, heart failure hospitalization, serum creatinine doubling, antihypertensive therapy
- MeSH terms
- Adult, Aged, Antihypertensive Agents, Cardiovascular Diseases, Creatine, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypertension, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Disease Progression, Losartan, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
